Heath Lab
Sort
Daniel Chen, an undergraduate researcher in ISB’s Heath Lab and junior at the University of Washington, has been awarded a prestigious Goldwater Scholarship. Chen has been a key member of ISB’s COVID-19 Immune Response Study.
Findings from the ISB-Swedish COVID-19 Immune Response Study suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The team studied 139 patients and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar.
In a multi-institutional study of a highly infectious disease like COVID-19, paperless consent for study participants is critical. One component of the COVID-19 Immune Response Study is a recruitment website with an IRB-approved and HIPAA-compliant electronic consent platform for enrolling patients.
In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.
ISB and Swedish Medical Center launched a study to follow hundreds of patients who contract COVID-19 to learn why those infected have drastically different outcomes. “Each of the COVID-19 patients has a unique lesson to teach us about how the medical and scientific community can respond most effectively to this pandemic,” said ISB President Dr. Jim Heath, who co-leads the study.
Members of ISB’s Heath Lab and their collaborators have developed a way to sensitively detect and analyze neoantigen-specific T-cell populations from tumors and blood. This promising development may have implications for creating targeted, individual-specific cancer vaccines.